New England Journal of Medicine publishes final overall survival data for Nubeqa ™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer (for specialized target groups only)

Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news